Last reviewed 2026-04-22 · How we verify

Escitalopram+Aripiprazole

This combination increases serotonin availability in the brain while blocking dopamine receptors to treat depression and related psychiatric conditions.

This combination increases serotonin availability in the brain while blocking dopamine receptors to treat depression and related psychiatric conditions. Used for Major depressive disorder, Treatment-resistant depression (augmentation therapy).

At a glance

Mechanism of action

Escitalopram is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake transporter. Aripiprazole is an atypical antipsychotic that acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors. Together, they provide augmented antidepressant and anxiolytic effects with reduced side effects compared to either agent alone.

Approved indications

• Major depressive disorder
• Treatment-resistant depression (augmentation therapy)

Common side effects

• Nausea
• Headache
• Insomnia
• Akathisia
• Weight gain
• Sexual dysfunction

Key clinical trials

• Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR. (PHASE4)
• Neurobiological Mechanisms of Pathological Rumination and Effects of Aripiprazole (NA)
• Treating Negative Affect in Low Back Pain Patients (PHASE2, PHASE3)
• Sequential Multiple Assignment Randomized Trial for Bipolar Depression (PHASE4)
• Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression (PHASE2)
• Personalized Indications for CBT and Antidepressants in Treating Depression (PHASE4)
• Psychopharmacotherapy for Depressive Patients (NA)
• Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.